Endovascular Aneurysm Repair (EVAR) Market Size, Share, Growth, and Industry Analysis, By Type (Abdominal Aortic Aneurysm (AAA), Thoracic Aortic Aneurysm (TAA)), By Application (Hospitals, Clinics, Ambulatory Surgical Centres), Regional Insights and Forecast to 2035
Endovascular Aneurysm Repair (EVAR) Market Overview
The global Endovascular Aneurysm Repair (EVAR) Market is anticipated to grow from USD 3285.64 Million in 2026 to USD 5664.36 Million by 2035, registering a CAGR of 6.24% during the forecast period 2026-2035.
The Endovascular Aneurysm Repair (EVAR) Market is expanding as healthcare systems prioritize minimally invasive treatment of abdominal and thoracic aortic aneurysms. Abdominal Aortic Aneurysm (AAA) represents an indicative 72% of procedural demand, supported by established screening practices, wider stent-graft availability, and favorable recovery characteristics. Increasing life expectancy, cardiovascular risk factors, and improved diagnostic imaging contribute to treatment demand. Modern endovascular systems incorporate flexible graft materials, advanced delivery catheters, and improved sealing mechanisms to accommodate challenging vascular anatomy. Hospitals increasingly use computed tomography angiography, three-dimensional reconstruction, and image-guided interventions to support treatment planning.
The United States Endovascular Aneurysm Repair (EVAR) Market benefits from advanced vascular surgery infrastructure, established reimbursement pathways, and continuous medical device innovation. The country accounts for an indicative 76% of North American procedural demand within this analytical framework. American hospitals are expanding multidisciplinary aortic programs that combine vascular surgery, interventional radiology, and cardiovascular imaging. Clinical decision-making increasingly emphasizes anatomical suitability, perioperative risk, device durability, and long-term imaging surveillance. Regulatory developments involving endograft labeling and investigational devices are supporting broader clinical evaluation.
Key Findings
- Market Driver: Rising demand for minimally invasive aneurysm treatment accelerates market growth, while mortality associated with ruptured abdominal aortic aneurysms can approach 80%, emphasizing the importance of timely diagnosis and effective intervention.
- Major Market Restraint: Complex vascular anatomy and high treatment costs restrict wider EVAR adoption, particularly in challenging thoracic procedures, with Thoracic Aortic Aneurysm (TAA) accounting for an indicative 28% market share.
- Emerging Trends: Advanced fenestrated and branched stent-graft technologies are transforming aneurysm treatment, with Abdominal Aortic Aneurysm (AAA) representing an indicative 72% market share and driving demand for personalized endovascular solutions.
- Regional Leadership: North America dominates the Endovascular Aneurysm Repair (EVAR) Market with an indicative 38% market share, supported by advanced cardiovascular treatment infrastructure, established vascular surgery programs, and increasing adoption of minimally invasive procedures.
- Competitive Landscape: Medtronic leads the indicative competitive assessment with a 17% market share, supported by its established Endurant stent-graft portfolio, continued regulatory developments, and strong presence in advanced endovascular aneurysm repair technologies.
- Market Segmentation: Abdominal Aortic Aneurysm (AAA) dominates the Endovascular Aneurysm Repair (EVAR) Market with an indicative 72% share, supported by established treatment practices, advanced stent-graft availability, and increasing demand for minimally invasive abdominal aneurysm interventions.
- Recent Development: W. L. Gore & Associates secured updated FDA labeling for its EXCLUDER aneurysm repair devices in July 2026, strengthening its clinical positioning and supporting its indicative 15% market share.
Endovascular Aneurysm Repair (EVAR) Market Latest Trends
Development of anatomically adaptable stent-graft technology is transforming the Endovascular Aneurysm Repair (EVAR) Market, with Abdominal Aortic Aneurysm (AAA) accounting for an indicative 72% market share. Fenestrated devices are designed to preserve blood flow through important arterial branches while excluding complex aneurysms from circulation. During 2026, medical device manufacturers advanced clinical evaluation of customized systems for difficult abdominal aortic anatomy. Modern treatment planning increasingly combines detailed computed tomography with three-dimensional vessel reconstruction and precise graft measurements. Branched endovascular systems are also receiving attention for thoracic and aortic arch conditions requiring preservation of blood supply to adjoining vessels.
Clinical emphasis on procedural safety, device durability, and post-treatment surveillance represents another significant market trend, particularly within Thoracic Aortic Aneurysm (TAA) procedures, which account for an indicative 28% market share. During 2026, manufacturers introduced regulatory updates, conducted device investigations, and reviewed product safety information to strengthen clinical decision-making. Healthcare providers increasingly evaluate proximal sealing performance, migration resistance, endoleak prevention, and delivery system reliability.
Endovascular Aneurysm Repair (EVAR) Market Dynamics
Driver
"Increasing demand for minimally invasive aortic aneurysm treatment."
Growing clinical preference for minimally invasive intervention remains a major market driver. Ruptured abdominal aortic aneurysms can carry mortality approaching 80%, emphasizing the importance of effective diagnosis, surveillance, and appropriate intervention. Endovascular repair offers selected patients an alternative to open surgery, generally involving smaller access incisions and less extensive surgical exposure. Improvements in vascular imaging and device delivery have increased procedural feasibility. Aging populations and established cardiovascular risk factors continue to contribute to the population requiring aneurysm assessment. Hospitals are strengthening specialist vascular services to address these clinical requirements.
Increasing access to advanced cardiovascular treatment infrastructure further supports demand. During 2026, specialist centers continued incorporating image-guided procedures and hybrid operating capabilities into vascular care. Endovascular intervention can offer shorter initial recovery and reduced perioperative burden for appropriately selected individuals, although long-term monitoring remains necessary. Multidisciplinary teams assess aneurysm dimensions, vessel morphology, access routes, and underlying medical conditions before determining treatment suitability.
Restraint
"Complex vascular anatomy and treatment costs restrict broader adoption."
Patient anatomy remains an important restraint because conventional endovascular devices require suitable proximal sealing zones and adequate vascular access, particularly in Thoracic Aortic Aneurysm (TAA) procedures, which represent an indicative 28% market share. Severe aortic neck angulation, calcification, vessel tortuosity, short landing zones, and involvement of arterial branches may prevent straightforward implantation. Advanced fenestrated or branched devices can address selected anatomical difficulties but require additional expertise and individualized planning. Procedural expenses, imaging requirements, and long-term surveillance obligations also influence healthcare purchasing and treatment decisions.
Limited availability of specialist facilities further restricts access across healthcare systems, particularly for complex Abdominal Aortic Aneurysm (AAA) interventions, which represent an indicative 72% market share. During 2026, complex aneurysm interventions remained dependent on trained vascular teams, reliable imaging equipment, and appropriate emergency support. Smaller hospitals may lack the infrastructure required to manage challenging anatomy or major procedural complications. Differences in reimbursement policies and availability of approved devices can affect treatment choices.
Opportunity
"Advanced graft customization expands complex aneurysm treatment opportunities."
Patient-specific endovascular technology offers important opportunities for manufacturers developing advanced aortic devices. In March 2026, Terumo Aortic announced FDA Breakthrough Device Designation for Fenestrated TREO, supporting development of a customized system for complex abdominal aneurysms. Fenestrated grafts can incorporate openings aligned with essential arterial branches, potentially accommodating anatomy beyond standard device indications. Improved planning software, lower-profile delivery systems, and personalized graft configurations support innovation. These developments also encourage investment in clinical trials, physician training, and specialized treatment infrastructure.
Emerging healthcare markets provide additional opportunities as vascular diagnosis and treatment capabilities improve. During 2026, companies expanded regulatory development and clinical applications across multiple international markets. Growing access to computed tomography, catheter-based procedures, and specialist medical training supports broader evaluation of endovascular repair. Manufacturers can improve accessibility through compatible delivery systems, clinician education, and regional service partnerships. Long-term market expansion will depend on demonstrating clinical safety, procedural effectiveness, and sustained device performance across diverse patient populations.
Challenge
"Long-term device surveillance and procedural complications require continued attention."
Endoleaks, device migration, graft integrity concerns, and continued aneurysm enlargement remain important challenges after treatment. During 2026, manufacturers and healthcare providers continued emphasizing device safety and post-implant imaging. Endovascular repair does not remove the underlying aneurysm, making continued observation necessary to identify changes in the excluded aneurysm sac. Some patients require secondary interventions when complications develop. Reliable surveillance depends on patient adherence, imaging availability, and effective coordination between treatment providers.
Product safety management represents another significant challenge for the industry. In July 2026, Terumo announced a voluntary recall affecting specified RelayPro thoracic stent-graft models following reported delivery system separation difficulties. The announcement highlighted the importance of manufacturing controls, device verification, and continuous safety monitoring. Regulatory scrutiny can affect clinical confidence and device availability. Manufacturers must therefore balance technological advancement with rigorous testing, transparent clinical evidence, and effective post-market surveillance systems.
Endovascular Aneurysm Repair (EVAR) Market Segmentation
By Types
Abdominal Aortic Aneurysm (AAA): Abdominal Aortic Aneurysm (AAA) accounts for an indicative 72% market share, representing the largest segment of the Endovascular Aneurysm Repair (EVAR) Market. Demand reflects established treatment practices, wider availability of compatible stent grafts, and increasing diagnosis among older adults. Endovascular abdominal repair commonly involves catheter-based deployment through femoral arterial access. Device selection depends on aneurysm morphology, vessel diameter, landing zone characteristics, and access suitability. Modern systems incorporate improved conformability, controlled deployment, and enhanced sealing designs to support procedural accuracy. Continued improvements in computed tomography planning and patient selection support demand for advanced abdominal endovascular systems.
Thoracic Aortic Aneurysm (TAA): Thoracic Aortic Aneurysm (TAA) represents an indicative 28% market share, supported by growing demand for specialized interventions involving the thoracic aorta. Thoracic endovascular procedures require careful assessment of aortic curvature, landing zones, and arterial branch involvement. Advanced stent-graft systems support treatment of selected descending thoracic aneurysms, while branched technologies address additional anatomical challenges. Treatment planning frequently involves multidisciplinary specialists because thoracic aortic disease may involve complex cardiovascular conditions and substantial procedural risks.Preservation of blood flow to critical arterial branches remains an important consideration. Long-term imaging surveillance is necessary to assess graft position, aneurysm exclusion, and potential complications. These requirements support demand from specialist cardiovascular centers with advanced procedural capabilities.
By Applications
Hospitals: Hospitals dominate the Endovascular Aneurysm Repair (EVAR) Market with an indicative 76% application share, supported by comprehensive surgical facilities and advanced diagnostic infrastructure. Complex aortic interventions frequently require vascular surgeons, anesthesiologists, imaging specialists, and intensive care teams. Hospitals typically provide hybrid operating rooms, computed tomography angiography, and emergency intervention services. Their ability to manage complicated anatomy and potential procedural emergencies makes them the primary treatment environment for aneurysm repair. Specialist referral networks further concentrate complex cases in established medical institutions.Hospital purchasing decisions emphasize clinical evidence, device compatibility, operational efficiency, and manufacturer support. Access to emergency surgical conversion capabilities remains particularly important for higher-risk interventions.
Clinics: Clinics account for an indicative 15% application share, reflecting their role in vascular diagnosis, patient evaluation, treatment coordination, and selected outpatient services. Specialist clinics support aneurysm screening, vascular imaging referrals, medical risk assessment, and follow-up monitoring. Although complex endovascular implantation is generally concentrated in hospitals, clinics contribute to patient identification and ongoing management. Their involvement helps establish continuity between initial diagnosis, specialist consultation, intervention planning, and post-treatment surveillance. Improved access to specialist consultation may support earlier assessment of patients requiring advanced aortic care.
Ambulatory Surgical Centres: Ambulatory Surgical Centres represent an indicative 9% application share, reflecting comparatively limited involvement in complex aneurysm interventions. These facilities support selected vascular procedures and associated outpatient care where clinical capabilities and regulatory requirements permit. Endovascular aneurysm repair frequently requires resources beyond those available in conventional ambulatory environments. Consequently, suitability depends on patient risk, procedural complexity, anesthesia requirements, and access to emergency services. Expansion of their procedural role requires careful assessment of infrastructure, staffing, and emergency transfer arrangements. Patient safety and case selection remain more important than procedural decentralization when evaluating this application category.
Endovascular Aneurysm Repair (EVAR) Market Regional Outlook
North America
North America leads the Endovascular Aneurysm Repair (EVAR) Market with an indicative 38% regional share, supported by advanced cardiovascular infrastructure and strong medical device availability. The United States remains the principal regional market, with Canada contributing through established vascular surgery services. Specialist hospitals offer comprehensive aneurysm assessment, endovascular treatment, and imaging surveillance. Regulatory progress involving aortic stent grafts encourages clinical evaluation of advanced technologies. Aging populations, cardiovascular risk factors, and extensive hospital referral networks further support regional treatment demand.Strong reimbursement infrastructure and established specialist expertise help maintain regional leadership, although access varies between healthcare systems and treatment centers.
Europe
Europe accounts for an indicative 29% market share, supported by established vascular surgery networks and increasing availability of advanced endovascular technologies. Germany, France, the United Kingdom, and other European markets maintain specialist centers offering abdominal and thoracic aneurysm treatment. Regional demand benefits from structured cardiovascular care pathways and widespread diagnostic imaging. Medical device manufacturers continue developing systems that address difficult vascular anatomy. Clinical assessment increasingly emphasizes anatomical suitability, device durability, and evidence supporting long-term treatment outcomes.Research collaborations and specialized training programs support procedural expertise. Differences in national healthcare budgets, device procurement practices, and specialist availability influence adoption patterns across individual countries.
Asia-Pacific
Asia-Pacific represents an indicative 25% regional share, supported by expanding cardiovascular treatment infrastructure and growing access to advanced medical technology. China, Japan, India, South Korea, and Australia contribute to demand through specialist hospitals and vascular intervention programs. Rising diagnostic capabilities and increasing awareness of aortic disease encourage earlier identification of patients requiring assessment. Local and international manufacturers are advancing device development, regulatory applications, and clinical training activities across the region. However, treatment availability remains uneven because of differences in specialist training, healthcare infrastructure, and medical device reimbursement.
Middle East and Africa
Middle East and Africa accounts for an indicative 5% regional share, reflecting developing vascular treatment capabilities and increasing investment in specialist healthcare infrastructure. Selected Gulf countries and major African medical centers offer advanced cardiovascular interventions, while access remains limited across smaller healthcare facilities. Demand is supported by medical infrastructure development and expanding availability of diagnostic imaging. Specialist physician training and access to advanced graft systems remain essential for broader adoption.International clinical partnerships may improve expertise and device accessibility. Affordability, specialist workforce availability, and follow-up infrastructure remain important considerations for sustained market development.
Rest of the World
Rest of the World represents an indicative 3% market share in the regional allocation, covering markets outside the principal geographical categories. Demand is influenced by gradual improvements in cardiovascular diagnosis, specialist services, and medical device distribution. Hospitals increasingly evaluate minimally invasive treatment options for selected aneurysm patients. Availability of advanced graft systems and vascular imaging varies considerably between healthcare systems, contributing to differences in procedural access.Continued investment in vascular infrastructure may gradually improve treatment availability across underserved healthcare markets.
List of Top Endovascular Aneurysm Repair (EVAR) Market Companies
- Medtronic
- Braile Biomedica
- Cook Group
- W. L. Gore & Associates
- JOTEC GmbH
- Terumo Corporation
- Nano Endoluminal
- Cardinal Health
- Microport
Top Two Companies with Highest Market Share
- Medtronic: Medtronic holds an illustrative 17% market share in the competitive framework, supported by its established Endurant abdominal stent-graft portfolio and extensive cardiovascular device expertise. The company emphasizes controlled graft deployment, clinical evidence, procedural training, and regulatory development. Its September 2026 European labeling milestone strengthened recognition of clinical evidence involving ruptured abdominal aortic aneurysms. The stated share is indicative rather than an independently verified measurement.
- W. L. Gore & Associates: W. L. Gore & Associates represents an illustrative 15% market share, supported by its EXCLUDER abdominal endoprostheses and TAG thoracic repair technologies. The company continues advancing device conformability, branch preservation, and clinical evidence development. Its July 2026 FDA labeling update strengthened the clinical positioning of established abdominal aneurysm repair systems. The indicated share represents an analytical estimate rather than a confirmed market measurement.
Investment Analysis and Opportunities
Investment activity in the Endovascular Aneurysm Repair (EVAR) Market increasingly emphasizes customized endografts, minimally invasive treatment systems, and advanced procedural imaging. During 2026, manufacturers pursued clinical investigations and regulatory pathways supporting complex abdominal and thoracic aortic interventions. Funding priorities include graft flexibility, precision delivery, anatomical compatibility, and long-term durability. Hospitals are also investing in specialist training, hybrid operating facilities, and imaging infrastructure. Companies developing reliable technologies for difficult aneurysm anatomy may gain opportunities in advanced cardiovascular centers.
Clinical research and regional expansion offer further investment potential across international markets. In 2026, investigational programs involving branched and fenestrated technologies demonstrated continued industry interest in difficult anatomical conditions. Manufacturers require sustained investment in clinical evidence, quality assurance, and regulatory documentation. Growth opportunities also involve clinician education, imaging-based treatment planning, and post-implant surveillance technologies. Successful commercialization depends on demonstrating patient benefit, procedural reliability, and acceptable long-term outcomes.
New Product Development
New product development emphasizes improved anatomical compatibility, precise graft placement, and preservation of important arterial branches. During 2026, investigational fenestrated and multi-branch systems advanced through regulatory evaluation and clinical development. These technologies are designed to support selected patients with anatomy unsuitable for conventional endovascular devices. Manufacturers are also improving delivery system flexibility, sealing mechanisms, and controlled deployment features. Imaging compatibility and patient-specific planning remain important considerations for future device innovation.
Safety engineering and procedural usability are equally important product development priorities. In 2026, manufacturers continued evaluating device reliability, graft durability, delivery catheter performance, and long-term clinical outcomes. Advanced endovascular systems increasingly incorporate features intended to support accurate positioning and reduce deployment complexity. Regulatory assessment and surveillance remain essential throughout product development. Innovation must balance treatment flexibility with dependable performance across different anatomical configurations.
Five Recent Developments
- March 2026 – Terumo Receives Breakthrough Designation for Fenestrated TREO: Terumo Corporation announced FDA Breakthrough Device Designation for its Fenestrated TREO Abdominal Stent-Graft System on March 16, 2026. The investigational device supports customized treatment of complex abdominal aortic aneurysms by preserving blood flow through important arterial branches.
- May 2026 – JOTEC Parent Expands Advanced Aortic Repair Portfolio: Artivion, the parent company of JOTEC GmbH, completed its acquisition of Endospan on May 18, 2026, adding the NEXUS endovascular aortic arch system to its cardiovascular treatment portfolio. The acquisition strengthens technological capabilities for complex aortic disease management.
- July 2026 – Gore Secures Updated Aneurysm Repair Device Labeling: W. L. Gore & Associates announced FDA labeling updates for its EXCLUDER AAA and Conformable AAA endoprostheses, incorporating clinical evidence involving ruptured abdominal aortic aneurysm treatment. The development strengthens its endovascular repair portfolio, with an indicative 15% market share in the supplied competitive assessment.
- August 2026 – Microport Advances Aorfix Regulatory Review in China: Microport announced on August 27, 2026, that its Aorfix abdominal aortic stent-graft system entered China's innovative medical device special review pathway. The development supports regulatory evaluation of advanced endovascular technology designed for patients with challenging aortic neck anatomy.
- September 2026 – Medtronic Receives European Aortic Device Labeling Update: Medtronic announced CE approval on September 3, 2026, for updated Endurant stent-graft labeling removing the warning related to ruptured abdominal aortic aneurysm treatment. This regulatory milestone strengthens its clinical positioning, supported by an illustrative 17% market share in the supplied competitive assessment.
Report Coverage
The Endovascular Aneurysm Repair (EVAR) Market report examines developments across the 2026–2035 forecast period, covering treatment demand, technological advances, market drivers, operational restraints, and investment opportunities. Product segmentation includes Abdominal Aortic Aneurysm (AAA) and Thoracic Aortic Aneurysm (TAA), while application coverage examines Hospitals, Clinics, and Ambulatory Surgical Centres. The analysis considers procedural planning, stent-graft innovation, vascular imaging, patient selection, and post-treatment surveillance. Competitive coverage evaluates the supplied medical device companies and their roles in advancing endovascular aortic technologies.
Regional analysis covers North America, Europe, Asia-Pacific, Middle East and Africa, and Rest of the World. The report evaluates healthcare infrastructure, specialist treatment availability, regulatory developments, and clinical innovation across these regions. It also reviews investment priorities, product development, manufacturer activities, and factors influencing medical device adoption. Segment allocations and company market shares are indicative analytical estimates that require independent validation before use as definitive market measurements.
Endovascular Aneurysm Repair (EVAR) Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 3285.64 Million in 2026 |
|
|
Market Size Value By |
USD 5664.36 Million by 2035 |
|
|
Growth Rate |
CAGR of 6.24% from 2026-2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation |
||
Frequently Asked Questions
The global Endovascular Aneurysm Repair (EVAR) Market is expected to reach USD 5664.36 Million by 2035.
The Endovascular Aneurysm Repair (EVAR) Market is expected to exhibit a CAGR of 6.24% by 2035.
Medtronic, Braile Biomedica, Cook Group, W. L. Gore & Associates, JOTEC GmbH, Terumo Corporation, Nano Endoluminal, Cardinal Health, Microport
In 2026, the Endovascular Aneurysm Repair (EVAR) Market value will reach at USD 3285.64 Million.